This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (21)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal

No

William Pryse-Phillips, MD
From Memorial University of Newfoundland, Canada

Arch Neurol. 1999;56:735-737.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ADDRESSING causative rather than symptomatic treatments, I suggest that the following are the appropriate goals of antidementia therapy: (1) to improve the patient's capacity to perform the basic or instrumental activities of daily living; (2) to improve the quality of life of the patient and/or the caregiver; (3) to improve memory and other cognitive and behavioral functions to the extent that this leads to clinically relevant improvements; and (4) to slow the course of the disease with respect to measurable cognitive decline and the level of care required, in comparison with placebo therapy.

Investigators of the ability of drugs to achieve such goals have employed neuropsychological tests, behavioral rating scales, and global ratings by clinicians or caregivers. The pertinence of the first of these is unclear: a 3-point change in the 70-point Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-COG) score represents a minor variation that may indicate the . . . [Full Text of this Article]

TACRINE


DONEPEZIL

SELEGILINE HYDROCHLORIDE

VITAMIN E

GINKGO BILOBA

OTHER AGENTS

CONCLUSIONS

RELATED ARTICLES

Treatment of Alzheimer Disease
Vladimir Hachinski
Arch Neurol. 1999;56(6):735.
EXTRACT | FULL TEXT  

Do We Have a Treatment for Alzheimer Disease?: Yes
Serge Gauthier
Arch Neurol. 1999;56(6):738-739.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Rockwood
J. Neurol. Neurosurg. Psychiatry 2004;75:677-685.
ABSTRACT | FULL TEXT  

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
Lanctot et al.
CMAJ 2003;169:557-564.
ABSTRACT | FULL TEXT  

Goal setting and attainment in Alzheimer's disease patients treated with donepezil
Rockwood et al.
J. Neurol. Neurosurg. Psychiatry 2002;73:500-507.
ABSTRACT | FULL TEXT  

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Rockwood et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:589-595.
ABSTRACT | FULL TEXT  

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
Wilcock et al.
BMJ 2000;321:1445-1445.
ABSTRACT | FULL TEXT  

Caregivers' preferences for the treatment of patients with Alzheimer's disease
Karlawish et al.
Neurology 2000;55:1008-1014.
ABSTRACT | FULL TEXT  

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
Raskind et al.
Neurology 2000;54:2261-2268.
ABSTRACT | FULL TEXT